Glaucoma News and Research

Latest Glaucoma News and Research

Decode Genetics announces Q2 2009 financials

deCODE genetics (Nasdaq: DCGN) today announced its consolidated financial results for the quarter ended June 30, 2009. A conference call to discuss these results and recent developments in the company's business will be webcast live tomorrow, Tuesday, August 11, at 8:00am Eastern Daylight Time/12 noon GMT/1pm British Summer Time (details below).

10 Aug 2009

Unlikely genetic suspect implicated in Dandy-Walker malformation

A genetic search that wound its way from patients to mouse models and back to patients has uncovered an unlikely gene critically involved in a common birth defect which causes mental retardation, motor delays and sometimes autism, providing a new mechanism and potentially improving treatment for the disorder.

9 Aug 2009

Factors linked to failure of corneal transplants

Certain eye conditions appear to put patients at greater risk for having a failed cornea transplant, according the Cornea Donor Study (CDS), a multi-center clinical trial conducted by the National Eye Institute. The study concludes that patients with glaucoma and patients who had corneal swelling following an earlier cataract surgery were more likely to experience failure of the cornea transplant than were other patients in the study.

11 Jun 2009

Lilly resubmits Cymbalta supplemental NDA for chronic pain to FDA

Eli Lilly and Company has resubmitted its supplemental New Drug Application (sNDA) for Cymbalta (duloxetine HCl) for the management of chronic pain to the U.S. Food and Drug Administration (FDA).

3 Jun 2009

Cell's split personality is a major discovery into neurological diseases

Researchers at the Université de Montreal (UdeM) and the Montreal Neurological Institute (MNI), McGill University have discovered that cells which normally support nerve cell (neuron) survival also play an active and major role in the death of neurons in the eye.

7 May 2009

Strange glaucoma puzzle solved

Scientists studying a rare form of glaucoma have discovered why people in the disparate Roma communities are at greater risk of inheriting a condition leading to permanent blindness than other groups in the population.

15 Apr 2009

Safety of Bitter orange herbal weight loss product questioned

The Australian Therapeutic Goods Administration (TGA) is reportedly examining whether there are any risks associated with an over-the-counter (OTC) herbal weight loss programme sold in Australia.

13 Apr 2009

CeNeRx BioPharma awarded patent for novel compounds that selectively target peripheral cannabinoid receptors

CeNeRx BioPharma, Inc. has announced issuance of a new U.S. patent covering its novel compounds that selectively target peripheral cannabinoid receptors.

1 Apr 2009

District Court decision received in Concerta patent sase

The U.S. District Court for the District of Delaware has rendered a decision in the patent litigation between Alza Corporation, McNeil-PPC, Inc. and Andrx Pharmaceuticals LLC. McNeil Pediatrics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., which markets Concerta (methylphenidate HCI) Extended-Release Tablets CII, said the court held that the patent in suit is not valid or infringed by the filing of Andrx's Abbreviated New Drug Application.

1 Apr 2009

Protein from tick saliva shows potential for myasthenia gravis treatment

Looking for a better treatment for the autoimmune disease myasthenia gravis, researchers have found that a protein in tick saliva shows promise in limiting the severity of the disease in an animal model in a study published in the Annals of Neurology.

29 Mar 2009

Positive phase 3 uveitis trial results for voclosporin

Isotechnika Inc. has announced that their partner, Lux Biosciences, Inc., reported the results from the three Phase 3 LUMINATE trials investigating voclosporin oral capsule (LUVENIQ or LX211) for the treatment of uveitis.

29 Mar 2009

Sirion Therapeutics sNDA for Durezol to treat uveitis accepted for FDA review

Sirion Therapeutics, Inc. announced today that its supplemental New Drug Application (sNDA) submitted to the U.S. Food and Drug Administration (FDA) seeking market approval of Durezol(TM) (difluprednate ophthalmic emulsion) 0.05% to treat endogenous anterior uveitis has been accepted for review.

16 Mar 2009

Shire withdraws European application for Daytrana (Methylphenidate Transdermal System)

Shire plc has announced that it has decided to withdraw the European Marketing Authorization Application (MAA) for Daytrana (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

16 Mar 2009

Blocking the dual leucine zipper kinase gene may help ease painful nerve condition

Scientists have identified the first gene that pulls the plug on ailing nerve cell branches from within the nerve cell, possibly helping to trigger the painful condition known as neuropathy.

15 Mar 2009

Experts discuss factors that may contribute to glaucoma

Although scientists know progressive degeneration of retinal ganglion cells and their axons is the primary cause of glaucoma, researchers have yet to identify a way to stop or prevent the degeneration.

4 Mar 2009

Aton Pharma acquires Timoptic product line from Merck & Co

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has acquired the U.S. marketing rights to the Timoptic product line from Merck & Co., Inc. Timoptic (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

25 Feb 2009

Protease inhibitor found to aid diabetic retinopathy treatment

Researchers from Joslin Diabetes Center, Boston, and ActiveSite Pharmaceuticals, Inc., San Francisco, announced today that they have demonstrated that a specific inhibitor of the protease plasma kallikrein, ASP-440, developed by ActiveSite Pharmaceuticals, may provide a new therapeutic approach for treatment of diabetic retinopathy, the most common eye-related complication of diabetes.

21 Jan 2009

Savella - Fibromyalgia treatment approved by FDA

Forest Laboratories, Inc. and Cypress Bioscience, Inc. have announced that Savella (milnacipran HCl), a selective serotonin and norepinephrine dual reuptake inhibitor, was approved by the U.S. Food and Drug Administration (FDA) for the management of fibromyalgia.

19 Jan 2009

Glaucoma may be linked to reading impairment in older adults

Glaucoma appears to be associated with slower spoken reading and increased reading impairment in older adults, according to a report in the January issue of Archives of Ophthalmology.

12 Jan 2009

New cataract early detection device

A compact fiber-optic probe developed for the space program has now proven valuable for patients in the clinic as the first non-invasive early detection device for cataracts, the leading cause of vision loss worldwide.

8 Jan 2009